LOS ANGELES, March 16, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
Mr. Eric Curtis, Advisor to the
Chairman and CEO, will present at the 28th Annual Oppenheimer
Healthcare Conference on Wednesday, March
21, 2018 at 3:55 P.M. Eastern Daylight Time at the
Westin New York Grand Central in New
York, New York.
A live and archived webcast of the presentation will be
available at:
https://www.veracast.com/webcasts/opco/healthcare2018/58216302815.cfm
About the 28th Annual Oppenheimer Healthcare
Conference
Investors will have the opportunity to hear and meet face to
face with over 100 corporate management leaders from public and
private companies at the forefront of the biopharmaceutical,
biotechnology, medical device, life science tools and diagnostics,
health technology and distribution, and healthcare facility,
provider and service industries. There will also be presentations
regarding emerging market opportunities and the current mergers and
acquisitions climate. This significant two-day Conference of
established institutional clients of Oppenheimer & Co. will be
held at the Westin New York Grand Central in New York, New York for two days from
Tuesday, March 20, 2018 through
Wednesday, March 21, 2018.
About the LADR™ Technology Platform
CytRx's innovative LADR™ (Linker Activated Drug Release)
technology platform employs a broad portfolio of novel linker
molecules that selectively bind to circulating albumin and can be
linked to a wide variety of anti-cancer payloads. The Company's
research efforts currently center on creating new molecules from
the combination of ultra-high potency cytotoxic payloads with
tunable linkers. The molecules that CytRx is currently
evaluating concentrate at the tumor site providing targeted
delivery of the cell killing payloads.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a
biopharmaceutical company specializing in research and clinical
development of novel anti-cancer drug candidates that employ linker
technologies to enhance the accumulation and release of drug at the
tumor. CytRx is rapidly expanding its pipeline of
ultra-high potency oncology candidates at its laboratory facilities
in Freiburg, Germany, through its LADR™ (Linker Activated Drug
Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker
technology for the development of a new class of potential
breakthrough anti-cancer
therapies. Aldoxorubicin, CytRx's most advanced drug
conjugate, is an improved version of the widely used anti-cancer
drug doxorubicin and has been out-licensed to NantCell,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to
obtain regulatory approval for its products that use aldoxorubicin;
the ability of NantCell, Inc., to manufacture and
commercialize products or therapies that use aldoxorubicin; the
amount, if any, of future milestone and royalty payments that we
may receive from NantCell, Inc.; our ability to develop new
ultra-high potency drug candidates based on our
LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date
of CytRx's most recent annual report. All forward-looking
statements are based upon information available
to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll/Sean Augustine-Obi
(212) 600-1902
michelle@argotpartners.com
sean@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-to-present-at-the-28th-annual-oppenheimer-healthcare-conference-300615133.html
SOURCE CytRx Corporation